LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects

LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects

LTX-315 is an oncolytic peptide that has antitumor efficacy in mice grafted with various tumor cell lines and is currently being tested in phase II clinical trials. Here we aimed to further evaluate LTX-315 in conditional genetic mouse models of cancer that typically resist current treatment options...

Full description

Bibliographic Details
Main Authors: Hsin-Wei Liao, Christopher Garris, Christina Pfirschke, Steffen Rickelt, Sean Arlauckas, Marie Siwicki, Rainer H. Kohler, Ralph Weissleder, Vibeke Sundvold-Gjerstad, Baldur Sveinbjørnsson, Øystein Rekdal, Mikael J. Pittet
Format: Article
Language:English
Published: Shared Science Publishers OG 2019-10-01
Series:Cell Stress
Subjects:
cancer
immunotherapy
oncolytic peptide
cd8+ t cells
melanoma
sarcoma
Online Access:http://www.cell-stress.com/researcharticles/2019a-liao-cell-stress/

Internet

http://www.cell-stress.com/researcharticles/2019a-liao-cell-stress/

Similar Items